BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Company News  |  Deals

Genzyme, sanofi-aventis deal

sanofi-aventis will acquire Genzyme for $74 per share in cash, or about $20.1 billion, plus a contingent value right worth up to $14 based on milestones through 2020. The cash portion is a 48% premium to Genzyme's close of $49.86 on July 1, before rumors surfaced that sanofi was considering an acquisition of a U.S. biotech company, including Genzyme.

The pharma reiterated plans to make Genzyme its global center for excellence in rare...

Read the full 349 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >